Abstract
Background
The aim of the study was to evaluate whether the therapy-induced reduction of the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment.
Methods
The study was performed as a part of a phase II trial evaluating cetuximab plus the leucovorin/5-fluorouracil/irinotecan (FOLFIRI) regimen. The objective response was evaluated according to the response evaluation criteria in solid tumors (RECIST) every 6 weeks. The early metabolic response evaluated by 18F-FDG-PET was assessed according to our own evaluated cutoff value (<35%) after receiver operating characteristic (ROC) analysis.
Results
Twenty of 22 patients had positive baseline 18F-FDG-PET. The best RECIST response was: complete response (CR), 3; partial response (PR), 9; stable disease (SD), 8. Twelve patients (60%) were classified as metabolic responders and 8 (40%) as nonresponders. At the median follow-up time of 11 months, median time to disease progression (TTP) and overall survival (OS) for early metabolic responders versus nonresponders were 11 versus 5 months (P = 0.0016) and 16 versus 6 months (P = 0.1493), respectively.
Conclusion
The early metabolic response evaluated by 18F-FDG-PET predicted the clinical outcome in this series of patients with advanced gastric cancer treated with chemotherapy plus cetuximab.
Article PDF
Similar content being viewed by others
References
F Kamangar GM Dores WF Anderson (2006) ArticleTitlePatterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137–50 Occurrence Handle16682732 Occurrence Handle10.1200/JCO.2005.05.2308
LE Hansson P Sparen O Nyren (1999) ArticleTitleSurvival in stomach cancer is improving: results of a nationwide population-based Swedish study Ann Surg 230 162–9 Occurrence Handle10450729 Occurrence Handle10.1097/00000658-199908000-00005 Occurrence Handle1:STN:280:DyaK1Mznsl2gug%3D%3D
JR Kelley JM Duggan (2003) ArticleTitleGastric cancer epidemiology and risk factors J Clin Epidemiol 56 1–9 Occurrence Handle12589864 Occurrence Handle10.1016/S0895-4356(02)00534-6
AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig (2006) ArticleTitleChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903–9 Occurrence Handle16782930 Occurrence Handle10.1200/JCO.2005.05.0245 Occurrence Handle1:CAS:528:DC%2BD28XntV2gs7s%3D
MA Shah RK Ramanathan DH Ilson A Levnor D D'Adamo E O'Reilly et al. (2006) ArticleTitleMulticenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 5201–6 Occurrence Handle17114652 Occurrence Handle10.1200/JCO.2006.08.0887 Occurrence Handle1:CAS:528:DC%2BD28XhtlemurbM
C Pinto F Di Fabio S Siena S Cascinu FL Rojas Llimpe C Ceccarelli et al. (2007) ArticleTitlePhase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX Study) Ann Oncol 18 510–7 Occurrence Handle17164226 Occurrence Handle10.1093/annonc/mdl459 Occurrence Handle1:STN:280:DC%2BD2s7hsVKjsA%3D%3D
E Mochiki H Kuwano H Katoh T Asao N Oriuchi K Endo (2004) ArticleTitleEvaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 247–53 Occurrence Handle14961197 Occurrence Handle10.1007/s00268-003-7191-5
SJ Rosenbaum H Stergar G Antoch P Veit A Bockisch H Kühl (2006) ArticleTitleStaging and follow-up of gastrointestinal tumors with PET/CT Abdom Imaging 31 25–35 Occurrence Handle16333707 Occurrence Handle10.1007/s00261-005-0031-3 Occurrence Handle1:STN:280:DC%2BD28%2FhsFGjug%3D%3D
SK Kim KW Kang JS Lee HK Kim HJ Chang JY Choi et al. (2006) ArticleTitleAssessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer Eur J Nucl Med Mol Imaging 33 148–55 Occurrence Handle16228236 Occurrence Handle10.1007/s00259-005-1887-8
L Kostakoglu SJ Goldsmith (2003) ArticleTitle18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma J Nucl Med 44 224–39 Occurrence Handle12571214
L Kostakoglu SJ Goldsmith (2004) ArticleTitlePET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus J Nucl Med 45 56–68 Occurrence Handle14734674
WA Weber (2005) ArticleTitleUse of PET for monitoring cancer therapy and for predicting outcome J Nucl Med 46 983–95 Occurrence Handle15937310 Occurrence Handle1:CAS:528:DC%2BD28XitFSqtrg%3D
C Rousseau A Devillers C Sagan L Ferre B Bridji L Campion et al. (2006) ArticleTitleMonitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography J Clin Oncol 24 5366–72 Occurrence Handle17088570 Occurrence Handle10.1200/JCO.2006.05.7406
WA Weber K Ott K Becker HJ Dittler H Helmberger NE Avril et al. (2001) ArticleTitlePrediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 3058–65 Occurrence Handle11408502 Occurrence Handle1:STN:280:DC%2BD3MzksFGhsQ%3D%3D
K Ott U Fink K Becker A Stahl HJ Dittler R Busch et al. (2003) ArticleTitlePrediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 4604–10 Occurrence Handle14673049 Occurrence Handle10.1200/JCO.2003.06.574 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWqurg%3D
K Ott WA Weber F Lordick K Becker R Busch K Hermann et al. (2006) ArticleTitleMetabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction J Clin Oncol 24 4692–8 Occurrence Handle16966684 Occurrence Handle10.1200/JCO.2006.06.7801
S Fanti R Franchi G Battista N Monetti R Canini (2005) ArticleTitlePET and PET-CT. State of the art and future prospects Radiol Med 11 1–15
P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubistein et al. (2000) ArticleTitleNew guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205–16 Occurrence Handle10655437 Occurrence Handle10.1093/jnci/92.3.205 Occurrence Handle1:STN:280:DC%2BD3c7it1Gitg%3D%3D
CE Metz (1989) ArticleTitleSome practical issues of experimental design and data analysis in radiologic ROC studies Invest Radiol 24 234–45 Occurrence Handle2753640 Occurrence Handle10.1097/00004424-198903000-00012 Occurrence Handle1:STN:280:BiaA38nns1c%3D
EL Kaplan P Meier (1958) ArticleTitleNonparametric estimation of incomplete observations J Am Stat Assoc 53 457–81 Occurrence Handle10.2307/2281868
JC Becker C Muller-Tidow H Serve W Domschke T Pohle (2006) ArticleTitleRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy World J Gastroenterol 12 3297–305 Occurrence Handle16733844 Occurrence Handle1:CAS:528:DC%2BD28XnsFWktrc%3D
M Schelling N Avril J Nährig W Kuhn W Römer D Sattler et al. (2000) ArticleTitlePositron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689–95 Occurrence Handle10764429 Occurrence Handle1:STN:280:DC%2BD3c3islyjsw%3D%3D
IC Smith AE Welch AW Hutcheon ID Miller S Payne F Chilcott et al. (2000) ArticleTitlePositron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676–88 Occurrence Handle10764428 Occurrence Handle1:STN:280:DC%2BD3c3islyjsg%3D%3D
L Kostakoglu M Coleman JP Leonard I Kuji H Zoe SJ Goldsmith (2002) ArticleTitlePET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease J Nucl Med 43 1018–27 Occurrence Handle12163626
E Brun E Kjellen J Tennvall T Ohlsson A Sandell R Perfekt et al. (2002) ArticleTitleFDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma Head Neck 24 127–35 Occurrence Handle11891942 Occurrence Handle10.1002/hed.10037
WA Weber V Petersen B Schmidt L Tyndale-Hines T Link C Peschel et al. (2003) ArticleTitlePositron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 2651–7 Occurrence Handle12860940 Occurrence Handle10.1200/JCO.2003.12.004 Occurrence Handle1:CAS:528:DC%2BD2cXptlCktLw%3D
K Ott WA Weber U Fink H Helmberger K Becker HJ Stein et al. (2003) ArticleTitleFluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia World J Surg 27 1035–9 Occurrence Handle12917760 Occurrence Handle10.1007/s00268-003-7058-9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fabio, F., Pinto, C., Rojas Llimpe, F. et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 10, 221–227 (2007). https://doi.org/10.1007/s10120-007-0438-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-007-0438-3